Bank of America
MBVX

Bank of America’s MABVAX THERAPEUTICS HLDGS INC MBVX Stock Holding History

Bank of America’s Portfolio MBVX Stock Details MBVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-6,664
Closed -$6K – 7698
2018
Q2 		$6K Buy
6,664
+333
+5% +$422 ﹤0.01% 6782
2018
Q1 		$10K Sell
6,331
-1
-0% -$2 ﹤0.01% 6620
2017
Q4 		$13K Hold
6,332
– – ﹤0.01% 6561
2017
Q3 		$12K Hold
6,332
– – ﹤0.01% 6494
2017
Q2 		$26K Buy
+6,332
New +$34.1K ﹤0.01% 6144
2017
Q1 		– Hold
0
– – – 7449
2016
Q4 		– Hold
0
– – – 7542

Other funds holding MBVX

PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
BCM
Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

Bank of America's MBVX Position: Q3 2018 in Review

Bank of America sold out of MABVAX THERAPEUTICS HLDGS INC (MBVX) in Q3 2018, closing a stake of 6,664 shares — an estimated $6K sold.

Bank of America first reported a position in MBVX in Q2 2017 and held it in 5 quarters. The position peaked at $26K in Q2 2017. 2 funds tracked by Wall St. Rank hold MBVX as of Q3 2018.

  • Bank of America reported no remaining MABVAX THERAPEUTICS HLDGS INC position as of Q3 2018 after selling out during the quarter.
  • Bank of America sold 6,664 MABVAX THERAPEUTICS HLDGS INC shares in Q3 2018, an estimated $6K.
  • Bank of America first reported a position in MABVAX THERAPEUTICS HLDGS INC in Q2 2017 and held it in 5 quarters.
  • Bank of America's MABVAX THERAPEUTICS HLDGS INC position peaked at $26K in Q2 2017.
  • 2 funds tracked by Wall St. Rank held MABVAX THERAPEUTICS HLDGS INC as of Q3 2018.

Based on Bank of America's 13F filing for Q3 2018, filed 14 Nov 2018.